CY1114566T1 - Δοσολογικη μορφη πραμιπεξολης χορηγουμενη μια φορα την ημερα - Google Patents
Δοσολογικη μορφη πραμιπεξολης χορηγουμενη μια φορα την ημεραInfo
- Publication number
- CY1114566T1 CY1114566T1 CY20131100969T CY131100969T CY1114566T1 CY 1114566 T1 CY1114566 T1 CY 1114566T1 CY 20131100969 T CY20131100969 T CY 20131100969T CY 131100969 T CY131100969 T CY 131100969T CY 1114566 T1 CY1114566 T1 CY 1114566T1
- Authority
- CY
- Cyprus
- Prior art keywords
- composition
- hours
- pramipexole
- absorption
- day
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Μια χορηγούμενη από το στόμα φαρμακευτική σύνθεση η οποία περιλαμβάνει μια θεραπευτικά αποτελεσματική ποσότητα πραμιπεξόλης ή ένα φαρμακευτικά αποδεκτό άλας αυτής και τουλάχιστον ένα φαρμακευτικά αποδεκτό έκδοχο, με την εν λόγω σύνθεση να επιδεικνύει τουλάχιστον ένα από τα: (α) προφίλ αποδέσμευσης στο δοκιμαστικό σωλήνα στο οποίο κατά μέσο όρο δε διαλύεται περισσότερο από 20% πραμιπεξόλης μέσα σε δυο ώρες από την τοποθέτηση της σύνθεσης σε μια πρότυπη δοκιμή διάλυσης και (β) προφίλ απορρόφησης της πραμιπεξόλης εσωσωματικά μετά τη χορήγηση μιας δόσης σε υγιείς ενήλικες ανθρώπους, στο οποίο ο χρόνος για να επιτευχθεί ένας μέσος όρος 20% απορρόφησης είναι μεγαλύτερος από περίπου 2 ώρες και/ή ο χρόνος για να επιτευχθεί ένας μέσος όρος 40% απορρόφησης είναι μεγαλύτερος από περίπου 4 ώρες. Η σύνθεση είναι χρήσιμη για χορήγηση από το στόμα, όχι περισσότερο από μια φορά την ημέρα, σε ένα άτομο που έχει μια κατάσταση ή διαταραχή για την οποία ενδείκνυται ένας αγωνιστής του υποδοχέα της ντοπαμίνης.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US39842702P | 2002-07-25 | 2002-07-25 | |
US39844702P | 2002-07-25 | 2002-07-25 | |
US47951403P | 2003-06-18 | 2003-06-18 | |
EP03771959.8A EP1536792B1 (en) | 2002-07-25 | 2003-07-25 | Pramipexole once-daily dosage form |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1114566T1 true CY1114566T1 (el) | 2016-10-05 |
Family
ID=31192088
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20131100643T CY1114263T1 (el) | 2002-07-25 | 2013-07-26 | Δοσολογικη μορφη πραμιπεξολης χορηγουμενη μια φορα την ημερα |
CY20131100969T CY1114566T1 (el) | 2002-07-25 | 2013-11-01 | Δοσολογικη μορφη πραμιπεξολης χορηγουμενη μια φορα την ημερα |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20131100643T CY1114263T1 (el) | 2002-07-25 | 2013-07-26 | Δοσολογικη μορφη πραμιπεξολης χορηγουμενη μια φορα την ημερα |
Country Status (40)
Country | Link |
---|---|
US (2) | US8679533B2 (el) |
EP (2) | EP2289514B9 (el) |
JP (1) | JP4607584B2 (el) |
KR (2) | KR20050025654A (el) |
CN (1) | CN1671381B (el) |
AP (1) | AP2223A (el) |
AR (1) | AR040682A1 (el) |
AU (1) | AU2003256921B2 (el) |
BR (1) | BR0312948A (el) |
CA (1) | CA2493629C (el) |
CU (1) | CU23468B7 (el) |
CY (2) | CY1114263T1 (el) |
DE (1) | DE20321906U1 (el) |
DK (2) | DK1536792T3 (el) |
EA (1) | EA017595B1 (el) |
EC (1) | ECSP055569A (el) |
ES (2) | ES2421787T3 (el) |
GE (1) | GEP20074047B (el) |
HK (1) | HK1078007A1 (el) |
HR (1) | HRP20041234B1 (el) |
IL (1) | IL166076A0 (el) |
IS (1) | IS7613A (el) |
MA (1) | MA27372A1 (el) |
ME (1) | ME00347B (el) |
MX (1) | MXPA05000980A (el) |
MY (1) | MY142204A (el) |
NO (1) | NO20050481L (el) |
NZ (1) | NZ562681A (el) |
OA (1) | OA12889A (el) |
PA (1) | PA8578501A1 (el) |
PE (1) | PE20040134A1 (el) |
PL (1) | PL375444A1 (el) |
PT (2) | PT2289514E (el) |
RS (1) | RS52764B (el) |
SG (1) | SG177011A1 (el) |
SI (2) | SI2289514T1 (el) |
TW (1) | TWI351955B (el) |
UY (1) | UY27913A1 (el) |
WO (1) | WO2004010999A1 (el) |
ZA (1) | ZA200500015B (el) |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050226926A1 (en) | 2002-07-25 | 2005-10-13 | Pfizer Inc | Sustained-release tablet composition of pramipexole |
US7365086B2 (en) * | 2003-07-25 | 2008-04-29 | Synthon Ip Inc. | Pramipexole acid addition salts |
CA2576386A1 (en) | 2004-08-13 | 2006-02-16 | Boehringer Ingelheim International Gmbh | Extended release pellet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof |
BRPI0513846A (pt) * | 2004-08-13 | 2008-05-20 | Boehringer Ingelheim Int | formulação de comprimido de liberação prolongada contendo pramipexol ou um sal farmaceuticamente aceitável do mesmo, método para a fabricação do mesmo e o uso do mesmo |
US20080038344A1 (en) * | 2004-10-01 | 2008-02-14 | Nippon Zoki Pharmaceutical Co., Ltd. | Solid Pharmaceutical Preparation |
WO2006046256A1 (en) * | 2004-10-27 | 2006-05-04 | Alembic Limited | Extended release formulation of pramipexole dihydrochloride |
WO2007090881A2 (en) * | 2006-02-10 | 2007-08-16 | Boehringer Ingelheim International Gmbh | Modified release formulation |
WO2007090883A1 (en) * | 2006-02-10 | 2007-08-16 | Boehringer Ingelheim International Gmbh | Extended release formulation |
WO2007090882A2 (en) * | 2006-02-10 | 2007-08-16 | Boehringer Ingelheim International Gmbh | Pharmaceutical extended release compositions comprising pramipexole |
US8518926B2 (en) * | 2006-04-10 | 2013-08-27 | Knopp Neurosciences, Inc. | Compositions and methods of using (R)-pramipexole |
ATE537826T1 (de) | 2006-05-16 | 2012-01-15 | Knopp Neurosciences Inc | Zusammensetzungen aus r(+)- und s(-)-pramipexol sowie verfahren zu ihrer anwendung |
US20080254118A1 (en) * | 2007-04-11 | 2008-10-16 | Hans-Werner Wernersbach | Process for preparing pramipexole dihydrochloride tablets |
US8524695B2 (en) | 2006-12-14 | 2013-09-03 | Knopp Neurosciences, Inc. | Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same |
EP2129382A4 (en) | 2007-02-21 | 2011-01-19 | Univ Michigan | COMPOSITIONS AND METHODS FOR TRANQUILIZATION OF THE CARDIAC MUSCLE |
US8519148B2 (en) | 2007-03-14 | 2013-08-27 | Knopp Neurosciences, Inc. | Synthesis of chirally purified substituted benzothiazole diamines |
JP2010527946A (ja) * | 2007-05-25 | 2010-08-19 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | プラミペキソールを含有する医薬製剤 |
US20080299189A1 (en) * | 2007-06-04 | 2008-12-04 | Drugtech Corporation | Controlled release dopamine agonist compositions |
EP2291178A4 (en) * | 2008-06-09 | 2013-07-24 | Supernus Pharmaceuticals Inc | PRAMIPEXOL FORMULATIONS WITH CONTROLLED RELEASE |
US20110190356A1 (en) | 2008-08-19 | 2011-08-04 | Knopp Neurosciences Inc. | Compositions and Methods of Using (R)- Pramipexole |
CA2749253A1 (en) * | 2009-04-09 | 2010-10-14 | Purdue Pharma | Once-daily oral ir/cr pramipexole formulation |
EP2448411A4 (en) * | 2009-07-02 | 2012-11-28 | Supernus Pharmaceuticals Inc | METHOD OF TREATING A NEUROLOGICAL DISORDER |
WO2011037976A2 (en) * | 2009-09-22 | 2011-03-31 | Dr. Reddy's Laboratories Limited | Pramipexole pharmaceutical formulations |
EP2525786A2 (en) * | 2010-01-18 | 2012-11-28 | Synthon BV | Pramipexole extended release tablets |
TR201001862A1 (tr) | 2010-03-11 | 2011-10-21 | Sanovel �La� San.Ve T�C.A.�. | Kontrollü salım gerçekleştiren pramipeksol formülasyonları. |
WO2011128914A2 (en) | 2010-04-15 | 2011-10-20 | Cadila Healthcare Limited | Extended release pharmaceutical compositions of pramipexole |
AU2011256928A1 (en) | 2010-05-24 | 2012-12-20 | Lupin Limited | Extended release formulation of pramipexole |
CN102670550A (zh) * | 2011-03-14 | 2012-09-19 | 北京天衡药物研究院 | 盐酸普拉克索渗透泵型控释片 |
WO2013034173A1 (en) | 2011-09-06 | 2013-03-14 | Synthon Bv | Pramipexole extended release tablets |
CN102406626B (zh) * | 2011-12-02 | 2013-08-28 | 深圳海王药业有限公司 | 盐酸普拉克索缓释片剂及其制备方法 |
WO2013096816A1 (en) | 2011-12-22 | 2013-06-27 | Biogen Idec Ma Inc. | Improved synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds |
EP2732812A1 (de) | 2012-11-15 | 2014-05-21 | Aristo Pharma GmbH | Pramipexol-Retardtablettenformulierung |
CN104744400B (zh) * | 2012-11-22 | 2017-08-11 | 北京三泉医药技术有限公司 | 用于治疗神经疾病的四氢苯并噻唑衍生物 |
US9662313B2 (en) | 2013-02-28 | 2017-05-30 | Knopp Biosciences Llc | Compositions and methods for treating amyotrophic lateral sclerosis in responders |
PT3019167T (pt) | 2013-07-12 | 2021-03-04 | Knopp Biosciences Llc | Tratamento de níveis elevados de eosinófilos e/ou basófilos |
US9468630B2 (en) | 2013-07-12 | 2016-10-18 | Knopp Biosciences Llc | Compositions and methods for treating conditions related to increased eosinophils |
AU2014306597B2 (en) | 2013-08-13 | 2018-05-17 | Knopp Biosciences Llc | Compositions and methods for treating chronic urticaria |
US9642840B2 (en) | 2013-08-13 | 2017-05-09 | Knopp Biosciences, Llc | Compositions and methods for treating plasma cell disorders and B-cell prolymphocytic disorders |
CN104606162B (zh) * | 2015-01-07 | 2017-03-29 | 海南康虹医药科技开发有限公司 | 一种盐酸普拉克索缓释制剂及其制备方法 |
CN104784155B (zh) * | 2015-05-15 | 2018-02-23 | 中国药科大学 | 一种盐酸普拉克索组合微丸胶囊及其制备方法 |
CN105030721B (zh) * | 2015-08-30 | 2018-05-04 | 南京康川济医药科技有限公司 | 一种含有盐酸普拉克索的口服固体组合物 |
JP6978417B2 (ja) * | 2016-10-07 | 2021-12-08 | トランスウェル・バイオテック・カンパニー・リミテッド | プラミペキソール経皮送達系及びその使用 |
CN110402304A (zh) * | 2016-12-21 | 2019-11-01 | 哈索赫伯特施密特有限两合公司 | 用于酸洗合成材料的酸洗液 |
CA3097332A1 (en) * | 2017-04-24 | 2018-11-01 | Chase Therapeutics Corporation | Composition comprising pramipexole and 5ht3 antagonist for treating dep ression |
US11234961B2 (en) | 2017-08-17 | 2022-02-01 | Zi-Qiang Gu | Pamoate salt of monoamine anti-Parkinson's agents, method of preparation and use thereof |
Family Cites Families (110)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2887440A (en) * | 1957-08-12 | 1959-05-19 | Dow Chemical Co | Enteric coating |
US3065143A (en) * | 1960-04-19 | 1962-11-20 | Richardson Merrell Inc | Sustained release tablet |
NL128902C (el) * | 1960-06-06 | |||
US3458622A (en) * | 1967-04-07 | 1969-07-29 | Squibb & Sons Inc | Controlled release tablet |
US3845770A (en) * | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
JPS58403B2 (ja) * | 1975-07-24 | 1983-01-06 | 武田薬品工業株式会社 | L− アスコルビンサンセイザイノ セイゾウホウ |
US4167558A (en) * | 1976-02-13 | 1979-09-11 | Hoffmann-La Roche Inc. | Novel sustained release tablet formulations |
US4140755A (en) * | 1976-02-13 | 1979-02-20 | Hoffmann-La Roche Inc. | Sustained release tablet formulations |
SE8003805L (sv) | 1980-05-21 | 1981-11-22 | Haessle Ab | En farmaceutisk beredning med forbettrade utlosningsegenskap |
SE8103843L (sv) * | 1981-06-18 | 1982-12-19 | Astra Laekemedel Ab | Farmaceutisk mixtur |
US4424235A (en) * | 1981-09-14 | 1984-01-03 | Hoffmann-La Roche Inc. | Hydrodynamically balanced controlled release compositions containing L-dopa and a decarboxylase inhibitor |
US4389393A (en) * | 1982-03-26 | 1983-06-21 | Forest Laboratories, Inc. | Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose |
EP0186087B1 (de) * | 1984-12-22 | 1989-08-23 | Dr. Karl Thomae GmbH | Tetrahydro-benzthiazole, deren Herstellung und deren Verwendung als Zwischenprodukte oder als Arnzneimittel |
US4738851A (en) * | 1985-09-27 | 1988-04-19 | University Of Iowa Research Foundation, Inc. | Controlled release ophthalmic gel formulation |
US4666612A (en) * | 1986-03-17 | 1987-05-19 | Kerr-Mcgee Chemical Corporation | Method for recovering a wood preservative from waste sludges |
US4772473A (en) * | 1986-06-16 | 1988-09-20 | Norwich Eaton Pharmaceuticals, Inc. | Nitrofurantoin dosage form |
US4709712A (en) * | 1986-10-22 | 1987-12-01 | Dermatalogical Products Of Texas | Polycarboxylic acid polymer gels as protective agents |
US4968508A (en) * | 1987-02-27 | 1990-11-06 | Eli Lilly And Company | Sustained release matrix |
US4789549A (en) * | 1987-03-09 | 1988-12-06 | Warner-Lambert Company | Sustained release dosage forms |
US4859470A (en) * | 1988-06-02 | 1989-08-22 | Alza Corporation | Dosage form for delivering diltiazem |
GB8828020D0 (en) * | 1988-12-01 | 1989-01-05 | Unilever Plc | Topical composition |
US5026559A (en) * | 1989-04-03 | 1991-06-25 | Kinaform Technology, Inc. | Sustained-release pharmaceutical preparation |
US5007790A (en) * | 1989-04-11 | 1991-04-16 | Depomed Systems, Inc. | Sustained-release oral drug dosage form |
US5133974A (en) * | 1989-05-05 | 1992-07-28 | Kv Pharmaceutical Company | Extended release pharmaceutical formulations |
US5273975A (en) * | 1989-06-09 | 1993-12-28 | The Upjohn Company | Heterocyclic amines having central nervous system activity |
FR2653337B1 (fr) | 1989-10-23 | 1992-02-07 | Dow Corning Sa | Element a liberation prolongee et procede pour le fabriquer. |
IE82916B1 (en) * | 1990-11-02 | 2003-06-11 | Elan Corp Plc | Formulations and their use in the treatment of neurological diseases |
EP0447168A3 (en) | 1990-03-16 | 1993-01-07 | Yamanouchi Pharmaceutical Co. Ltd. | Long acting granular pharmaceutical composition |
US5472712A (en) * | 1991-12-24 | 1995-12-05 | Euroceltique, S.A. | Controlled-release formulations coated with aqueous dispersions of ethylcellulose |
US5681585A (en) * | 1991-12-24 | 1997-10-28 | Euro-Celtique, S.A. | Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer |
US5656296A (en) * | 1992-04-29 | 1997-08-12 | Warner-Lambert Company | Dual control sustained release drug delivery systems and methods for preparing same |
US5661171A (en) * | 1992-07-02 | 1997-08-26 | Oramed, Inc. | Controlled release pilocarpine delivery system |
ATE219933T1 (de) | 1992-09-18 | 2002-07-15 | Yamanouchi Pharma Co Ltd | Hydrogelzubereitung mit verzögerter freisetzung |
DE4241013A1 (de) * | 1992-12-05 | 1994-06-09 | Boehringer Ingelheim Kg | Verwendung von 2-Amino-6-n-propyl-amino-4,5,6,7-tetrahydrobenzothiazol als Arzneimittel mit antidepressiver Wirkung |
US5431920A (en) * | 1993-09-21 | 1995-07-11 | Merck Frosst, Canada, Inc. | Enteric coated oral compositions containing bisphosphonic acid antihypercalcemic agents |
US5458887A (en) * | 1994-03-02 | 1995-10-17 | Andrx Pharmaceuticals, Inc. | Controlled release tablet formulation |
US5484608A (en) | 1994-03-28 | 1996-01-16 | Pharmavene, Inc. | Sustained-release drug delivery system |
DE4432757A1 (de) | 1994-09-14 | 1996-03-21 | Boehringer Mannheim Gmbh | Pharmazeutische Zubereitung enthaltend Metformin und Verfahren zu deren Herstellung |
US5650420A (en) | 1994-12-15 | 1997-07-22 | Pharmacia & Upjohn Company | Pramipexole as a neuroprotective agent |
WO1997004752A1 (en) | 1995-07-26 | 1997-02-13 | Duramed Pharmaceuticals, Inc. | Pharmaceutical compositions of conjugated estrogens and methods for their use |
CN1146401C (zh) | 1995-12-27 | 2004-04-21 | 詹森药业有限公司 | 生物粘着固体剂型 |
US5846971A (en) * | 1996-06-28 | 1998-12-08 | Schering Corporation | Oral antifungal composition |
JPH1017497A (ja) | 1996-07-02 | 1998-01-20 | Takeda Chem Ind Ltd | 徐放性製剤およびその製造方法 |
GB9619074D0 (en) | 1996-09-12 | 1996-10-23 | Smithkline Beecham Plc | Composition |
ES2248908T7 (es) * | 1997-06-06 | 2014-11-24 | Depomed, Inc. | Formas de dosificación de fármacos por vía oral y retención gástrica para liberación continuada de fármacos altamente solubles |
AU8293498A (en) | 1997-07-02 | 1999-01-25 | Euro-Celtique S.A. | Stabilized sustained release tramadol formulations |
CA2211778A1 (en) | 1997-08-14 | 1999-02-14 | Francois Carriere | Preparation of pregelatinized high amylose starch and debranched starch useful as an excipient for controlled release of active agents |
DE69819748T2 (de) * | 1997-09-12 | 2004-09-30 | Columbia Laboratories (Bermuda) Ltd. | Arzneimittel zur behandlung von dysmenorrhöe und verfrühten wehen |
US6624200B2 (en) * | 1998-08-25 | 2003-09-23 | Columbia Laboratories, Inc. | Bioadhesive progressive hydration tablets |
US7153845B2 (en) * | 1998-08-25 | 2006-12-26 | Columbia Laboratories, Inc. | Bioadhesive progressive hydration tablets |
US6248358B1 (en) * | 1998-08-25 | 2001-06-19 | Columbia Laboratories, Inc. | Bioadhesive progressive hydration tablets and methods of making and using the same |
DE69814428T2 (de) | 1997-09-29 | 2004-05-13 | Nektar Therapeutics, San Carlos | In verneblern verwendbare, stabilisierte zubereitungen |
US6197339B1 (en) | 1997-09-30 | 2001-03-06 | Pharmacia & Upjohn Company | Sustained release tablet formulation to treat Parkinson's disease |
US6056977A (en) * | 1997-10-15 | 2000-05-02 | Edward Mendell Co., Inc. | Once-a-day controlled release sulfonylurea formulation |
US20020013304A1 (en) | 1997-10-28 | 2002-01-31 | Wilson Leland F. | As-needed administration of an androgenic agent to enhance female sexual desire and responsiveness |
US20020054911A1 (en) * | 2000-05-11 | 2002-05-09 | Boehringer Mannheim Pharmaceutical Corporation-Sm Ithkline Beckman Corporation, Limited Partnershi | Novel oral dosage form for carvedilol |
FR2772615B1 (fr) | 1997-12-23 | 2002-06-14 | Lipha | Comprime multicouche pour la liberation instantanee puis prolongee de substances actives |
GB9802201D0 (en) | 1998-02-03 | 1998-04-01 | Cerestar Holding Bv | Free-flowable directly compressible starch as binder,disintegrant and filler for compresion tablets and hard gelatine capsules |
CA2323177A1 (en) | 1998-03-11 | 1999-09-16 | Susan Marie Milosovich | Composition |
EA200300125A1 (ru) | 1998-05-15 | 2003-06-26 | Фармация Энд Апджон Компани | Применение каберголина для лечения полисистемной атрофии и прогрессирующего супрануклеарного паралича |
US6312728B1 (en) | 1998-07-07 | 2001-11-06 | Cascade Development, Inc. | Sustained release pharmaceutical preparation |
TW407058B (en) * | 1998-07-17 | 2000-10-01 | Dev Center Biotechnology | Oral cisapride dosage forms with an extended duration |
US20010055613A1 (en) | 1998-10-21 | 2001-12-27 | Beth A. Burnside | Oral pulsed dose drug delivery system |
US6270805B1 (en) | 1998-11-06 | 2001-08-07 | Andrx Pharmaceuticals, Inc. | Two pellet controlled release formulation for water soluble drugs which contains an alkaline metal stearate |
US7374779B2 (en) * | 1999-02-26 | 2008-05-20 | Lipocine, Inc. | Pharmaceutical formulations and systems for improved absorption and multistage release of active agents |
BR0009437A (pt) * | 1999-03-31 | 2002-01-15 | Janssen Pharmaceutica Nv | Amido pré-gelatinizado em uma formulação de liberação controlada |
DE19927688A1 (de) | 1999-06-17 | 2000-12-21 | Gruenenthal Gmbh | Mehrschichttablette zur Verabreichung einer fixen Kombination von Tramadol und Diclofenac |
ATE431141T1 (de) * | 1999-07-13 | 2009-05-15 | Alpha Res Group Llc | Zusammensetzungen und verfahren zur behandlung der parkinson-krankheit |
GB9923045D0 (en) | 1999-09-29 | 1999-12-01 | Novartis Ag | New oral formulations |
AU7620600A (en) | 1999-09-30 | 2001-04-30 | General Hospital Corporation, The | Use of pramipexole as a treatment for cocaine craving |
CN1409630A (zh) | 1999-10-19 | 2003-04-09 | Nps药物有限公司 | 用于治疗cns-失调疾病之持续释放型制剂 |
US20030180352A1 (en) * | 1999-11-23 | 2003-09-25 | Patel Mahesh V. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
KR20020082473A (ko) * | 1999-12-22 | 2002-10-31 | 파마시아 코포레이션 | 시클로옥시게나제-2 억제제의 지속-방출 조제물 |
US6467637B2 (en) * | 2000-01-27 | 2002-10-22 | The York Group, Inc. | Death care merchandising system |
OA12215A (en) | 2000-02-08 | 2006-05-09 | Euro Celtique Sa | Tamper-resistant oral opioid agonist formulations. |
PE20011074A1 (es) * | 2000-02-23 | 2001-10-04 | Upjohn Co | Uso de pramipexol en el tratamiento de trastornos de adiccion |
CN1396829A (zh) * | 2000-02-24 | 2003-02-12 | 法玛西雅厄普约翰美国公司 | 新的药物联合形式 |
US6372252B1 (en) | 2000-04-28 | 2002-04-16 | Adams Laboratories, Inc. | Guaifenesin sustained release formulation and tablets |
US6955821B2 (en) * | 2000-04-28 | 2005-10-18 | Adams Laboratories, Inc. | Sustained release formulations of guaifenesin and additional drug ingredients |
US6277875B1 (en) * | 2000-07-17 | 2001-08-21 | Andrew J. Holman | Use of dopamine D2/D3 receptor agonists to treat fibromyalgia |
EP1318813A4 (en) * | 2000-08-08 | 2005-09-07 | Teva Pharma | STABLE PERGOLIDE MESYLATE AND PROCESS FOR MAKING SAME |
ES2187249B1 (es) * | 2000-09-18 | 2004-09-16 | Synthon Bv | Procedimiento para la preparacion de 2-amino-6-(alquil)amino-4,5,6,7-tetrahidrobenzotiazoles. |
SE0004671D0 (sv) * | 2000-12-15 | 2000-12-15 | Amarin Dev Ab | Pharmaceutical formulation |
AU2002355686B2 (en) | 2001-07-04 | 2007-11-29 | Sun Pharmaceutical Industries Limited | Gastric retention controlled drug delivery system |
FR2827872A1 (fr) | 2001-07-30 | 2003-01-31 | Roussy Inst Gustave | Vesicules membranaires de fluide biologique preleve in vivo, leur preparation et utilisation dans la stimulation d'une reponse immunitaire |
US20030032661A1 (en) * | 2001-08-02 | 2003-02-13 | Boehringer Ingelheim Pharma Kg | Pramipexole as an anticonvulsant |
GB0125088D0 (en) | 2001-10-18 | 2001-12-12 | Smithkline Beecham Cork Ltd | New use |
CA2470636A1 (en) * | 2001-12-20 | 2003-07-03 | Pharmacia Corporation | Zero-order sustained released dosage forms and method of making the same |
MXPA04006522A (es) | 2002-01-04 | 2004-10-04 | Ivax Research Inc | Sistema de suministro de medicamentos para el suministro sostenido de glipizida. |
EP1480618B1 (en) | 2002-03-04 | 2009-06-03 | Ipsen Pharma | Sustained release drug formulations containing a carrier peptide |
EP2425823A1 (en) | 2002-04-05 | 2012-03-07 | Euro-Celtique S.A. | Pharmaceutical preparation containing oxycodone and naloxone |
WO2003088952A1 (en) | 2002-04-15 | 2003-10-30 | Adams Laboratories, Inc. | Sustained release of guaifenesin combination drugs |
US20030215498A1 (en) * | 2002-05-17 | 2003-11-20 | Harland Ronald S. | Rapidly disintegrating comressed tablets comprising biologically active compounds |
BR0311693A (pt) | 2002-06-10 | 2005-03-22 | Wyeth Corp | Sal de formato de o-desmetil-venlafaxina |
MXPA05000018A (es) | 2002-06-27 | 2005-04-08 | Cilag Ag | Formulaciones de pellas esfericas. |
AU2003281181A1 (en) * | 2002-07-11 | 2004-02-02 | Takeda Pharmaceutical Company Limited | Process for producing coated preparation |
US20050226926A1 (en) * | 2002-07-25 | 2005-10-13 | Pfizer Inc | Sustained-release tablet composition of pramipexole |
AR040680A1 (es) * | 2002-07-25 | 2005-04-13 | Pharmacia Corp | Composicion de tabletas de liberacion sostenida |
US20040137156A1 (en) | 2002-07-25 | 2004-07-15 | Lee Ernest J | Coated solid dosage form and method for preparing same |
US20040121010A1 (en) * | 2002-10-25 | 2004-06-24 | Collegium Pharmaceutical, Inc. | Pulsatile release compositions of milnacipran |
WO2004058228A1 (en) | 2002-12-24 | 2004-07-15 | Lupin Limited | Enteric coated fluoxetine composition |
CA2415154C (en) | 2002-12-24 | 2009-06-16 | Biovail Laboratories Inc. | Modified release formulations of selective serotonin re-uptake inhibitors |
US20050020589A1 (en) * | 2003-06-18 | 2005-01-27 | Pfizer Inc. | Sustained-release tablet composition comprising a dopamine receptor agonist |
CA2576386A1 (en) * | 2004-08-13 | 2006-02-16 | Boehringer Ingelheim International Gmbh | Extended release pellet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof |
BRPI0513846A (pt) * | 2004-08-13 | 2008-05-20 | Boehringer Ingelheim Int | formulação de comprimido de liberação prolongada contendo pramipexol ou um sal farmaceuticamente aceitável do mesmo, método para a fabricação do mesmo e o uso do mesmo |
WO2007090883A1 (en) * | 2006-02-10 | 2007-08-16 | Boehringer Ingelheim International Gmbh | Extended release formulation |
WO2007090881A2 (en) * | 2006-02-10 | 2007-08-16 | Boehringer Ingelheim International Gmbh | Modified release formulation |
EP1886665A1 (en) * | 2006-08-01 | 2008-02-13 | Boehringer Ingelheim Pharma GmbH & Co. KG | Gastro retentive delivery system |
CL2007002214A1 (es) * | 2006-08-14 | 2008-03-07 | Boehringer Ingelheim Int | Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp |
EA200900270A1 (ru) * | 2006-08-25 | 2009-08-28 | Бёрингер Ингельхайм Интернациональ Гмбх | Системы регулируемого высвобождения и способ их приготовления |
-
2003
- 2003-07-24 PA PA20038578501A patent/PA8578501A1/es unknown
- 2003-07-24 AR AR20030102667A patent/AR040682A1/es unknown
- 2003-07-24 PE PE2003000736A patent/PE20040134A1/es not_active Application Discontinuation
- 2003-07-24 US US10/626,275 patent/US8679533B2/en active Active
- 2003-07-24 MY MYPI20032783A patent/MY142204A/en unknown
- 2003-07-25 WO PCT/US2003/023522 patent/WO2004010999A1/en active Application Filing
- 2003-07-25 EP EP10174089.2A patent/EP2289514B9/en not_active Expired - Lifetime
- 2003-07-25 JP JP2004524936A patent/JP4607584B2/ja not_active Expired - Fee Related
- 2003-07-25 DE DE20321906U patent/DE20321906U1/de not_active Expired - Lifetime
- 2003-07-25 OA OA1200500017A patent/OA12889A/en unknown
- 2003-07-25 MX MXPA05000980A patent/MXPA05000980A/es unknown
- 2003-07-25 CN CN038178311A patent/CN1671381B/zh not_active Expired - Fee Related
- 2003-07-25 KR KR1020057001294A patent/KR20050025654A/ko not_active Application Discontinuation
- 2003-07-25 ME MEP-2008-522A patent/ME00347B/me unknown
- 2003-07-25 EP EP03771959.8A patent/EP1536792B1/en not_active Expired - Lifetime
- 2003-07-25 PL PL03375444A patent/PL375444A1/xx unknown
- 2003-07-25 PT PT101740892T patent/PT2289514E/pt unknown
- 2003-07-25 BR BR0312948-9A patent/BR0312948A/pt not_active IP Right Cessation
- 2003-07-25 CA CA2493629A patent/CA2493629C/en not_active Expired - Fee Related
- 2003-07-25 RS RS115104A patent/RS52764B/en unknown
- 2003-07-25 AP AP2005003206A patent/AP2223A/xx active
- 2003-07-25 ES ES10174089T patent/ES2421787T3/es not_active Expired - Lifetime
- 2003-07-25 GE GEAP8598A patent/GEP20074047B/en unknown
- 2003-07-25 NZ NZ562681A patent/NZ562681A/en not_active IP Right Cessation
- 2003-07-25 EA EA200500080A patent/EA017595B1/ru not_active IP Right Cessation
- 2003-07-25 AU AU2003256921A patent/AU2003256921B2/en not_active Expired
- 2003-07-25 KR KR1020077012380A patent/KR101066374B1/ko not_active IP Right Cessation
- 2003-07-25 DK DK03771959.8T patent/DK1536792T3/da active
- 2003-07-25 SG SG2008086357A patent/SG177011A1/en unknown
- 2003-07-25 SI SI200332276T patent/SI2289514T1/sl unknown
- 2003-07-25 TW TW092120436A patent/TWI351955B/zh not_active IP Right Cessation
- 2003-07-25 DK DK10174089.2T patent/DK2289514T5/da active
- 2003-07-25 PT PT37719598T patent/PT1536792E/pt unknown
- 2003-07-25 ES ES03771959.8T patent/ES2436745T3/es not_active Expired - Lifetime
- 2003-07-25 SI SI200332311T patent/SI1536792T1/sl unknown
- 2003-07-31 UY UY27913A patent/UY27913A1/es not_active Application Discontinuation
-
2004
- 2004-12-23 IS IS7613A patent/IS7613A/is unknown
- 2004-12-30 HR HRP20041234AA patent/HRP20041234B1/hr not_active IP Right Cessation
- 2004-12-30 IL IL16607604A patent/IL166076A0/xx unknown
-
2005
- 2005-01-03 ZA ZA200500015A patent/ZA200500015B/en unknown
- 2005-01-24 EC EC2005005569A patent/ECSP055569A/es unknown
- 2005-01-25 CU CU20050019A patent/CU23468B7/es unknown
- 2005-01-25 MA MA28067A patent/MA27372A1/fr unknown
- 2005-01-27 NO NO20050481A patent/NO20050481L/no not_active Application Discontinuation
- 2005-11-09 HK HK05109990.6A patent/HK1078007A1/xx not_active IP Right Cessation
-
2013
- 2013-07-26 CY CY20131100643T patent/CY1114263T1/el unknown
- 2013-11-01 CY CY20131100969T patent/CY1114566T1/el unknown
-
2014
- 2014-01-28 US US14/165,743 patent/US20140141079A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1114566T1 (el) | Δοσολογικη μορφη πραμιπεξολης χορηγουμενη μια φορα την ημερα | |
CY1109270T1 (el) | Ανθεκτικα στην παραβιαση στοματικα σκευασματα οπιουχων αγωνιστων | |
NO20051854L (no) | Vedvarende frigivelse opioidformuleringer og fremgangsmater for anvendelse. | |
AR045972A1 (es) | Formulaciones de tramadol de liberacion sostenida con eficacia de 24 horas | |
CY1106727T1 (el) | Ινδανυλ παραγωγα για την αντιμετωπιση ασθενειων αεραγωγων | |
NO20052019L (no) | Blanding for a inhibere sekresjon av magesyre | |
CY1117470T1 (el) | Στερεα δοσολογικα σκευασματα με βελτιωμενη ενδοστοματικη προσροφηση | |
ECSP056194A (es) | Derivados de pirazolo-quinazolina, procedimiento para su preparacion y su uso como inhibidores de quinasa | |
CY1105120T1 (el) | Η αντιμετωπιση αναπνευστικων νοσων | |
UY30537A1 (es) | Formulaciones de flibanserina y metodo para fabricarlas | |
AR058163A1 (es) | Medicamentos exhaltadores del deseo sexual que comprenden derivados de benzimidazolona | |
DE69831869D1 (de) | Verbesserte verabreichungstechnik für multiple medikamentengaben | |
ES2091877T3 (es) | Uso de antagonistas de la angiotensina ii para la fabricacion de un medicamento para el tratamiento de la hiperuricemia. | |
CO5011096A1 (es) | Medicamentos que contienen antagonistas del receptor 5-ht3 para el tratamiento de la ibs | |
CY1107096T1 (el) | Μεθοδοι και φαρμακοτεχνικες μορφες ελεγχομενης απελευθερωσης παλιπεριδονης | |
ES2181417T3 (es) | Formulacion de capsulas o tabletas de efavirenz de disolucion rapida usando super-desintegrantes. | |
CY1114073T1 (el) | Μεθοδοι χρησης συνθεσεων αμινοπυριδινης παρατεταμενης αποδεσμευσης | |
AR040709A1 (es) | Formulacion de lamotrigina de liberacion prolongada y uso de la misma para su preparacion | |
ATE505203T1 (de) | Pharmazeutische kombination aus aliskiren und valsartan | |
RU98102392A (ru) | Производные дифенилметиленпиперидина | |
AR062659A1 (es) | Composicion de liberacion sostenida de levodopa y metodo para su uso | |
ES2524369T3 (es) | Unidad de dosificación que incluye un análogo de prostaglandina para el tratamiento del estreñimiento | |
AR025046A1 (es) | Inhibidores il-5 no esteroidales, procedimientos e intermediarios para su preparacion y composiciones farmaceuticas que comprenden dichos inhibidores | |
BRPI0412430A (pt) | polipeptìdeo agonista do receptor de zot e zonulina | |
ECSP11010999A (es) | Combinación de dosis fija en la forma de una tableta de dos capas o de una sola capa de alisquireno y amlodipina |